MENU
Nowości i wydarzenia
QbD Group ogłasza przejęcie SciencePharma, wzmacniając globalne kompetencje w zakresie Regulatory Affairs i GMP
Antwerpia, Belgia / Warszawa, Polska – 4 grudnia 2024 r. – QbD Group i SciencePharma zawarły porozumienie w sprawie zakupu przez QbD Group 100% udziałów SciencePharma. Finalizacja transakcji spodziewana jest na początek 2025 roku, pod warunkiem uzyskania zgody organów antymonopolowych (Urząd Ochrony Konkurencji i Konsumentów). QbD Group, prywatna firma oferująca kompleksowe wsparcie dla firm z […]
EMA: Guideline on the Development and Manufacture of Synthetic peptides.
On 12 October 2023, the European Medicines Agency (EMA) published the draft Guideline on the Development and Manufacture of Synthetic peptides. In addition to the current lack of specific guidelines, EMA cited increased industry interest in developing peptide medicines as a motivation for developing the proposed guidelines. At SciencePharma we are always up to date […]
Akredytacja dla SciencePharma w unijnym projekcie „SPEKTRUM”
W ramach projektu „Spektrum” nasza firma została wpisana do Bazy Instytucji Otoczenia Biznesu. Miło jest nam ogłosić, że w dniu 13 września 2022 SciencePharma została wpisana do bazy Instytucji Otoczenia Biznesu w projekcie „SPEKTRUM” w kategorii usług techniczno – środowiskowych. System SPEKTRUM jest finansowany z funduszy Unii Europejskiej. Jest realizowany przez Agencję Rozwoju Pomorza (ARP). Całkowita wartość projektu […]
The Windsor Framework: MHRA to Take Full Control of Medicines Regulation in Northern Ireland
On the 24th of March 2023, the United Kingdom and the European Union formally adopted the Windsor Framework agreement concerning Brexit for Northern Ireland. This agreement sets out arrangements to solve problems and challenges following the exit of Great Britain from the EU. The new version of the document introduces solutions that will make the […]
Public consultation on ICH E6(R3) Guideline on good clinical practice (GCP)
On 26 May 2023, the European Medicines Agency (EMA) published the draft ICH E6 (R3) guideline on good clinical practice (GCP) – step 2b and the template for comments to the ICH E6 (R3) guideline on good clinical practice. The document has been submitted for public consultation and the comments will be collected until September […]
CEP 2.0 as new certification form issued by EDQM for demonstrating substance used in the preparation of medicinal products compliance with the European Pharmacopoeia
The CEP, as you know, is a “Certificate of suitability to the monographs of the European Pharmacopoeia“. As we can read on the EDQM (European Directorate for the Quality of Medicines and HealthCare) website it is not mandatory, but the preferred option for demonstrating that a substance used in the preparation of medicinal products complies […]
RAPS: New FDA Warning Letters Highlight CGMP Deviations at API Plants in China, India
The US Food and Drug Administration (FDA) on Tuesday released two new warning letters for active pharmaceutical ingredient manufacturers Badrivishal Chemicals & Pharmaceuticals and Lumis Global Pharmaceuticals, both sent 2 March. The letter for Talegaon Dabhade, India-based Badrivishal follows a three-day inspection from last August in which FDA uncovered that the site’s water purification system […]
EMA: Regulatory cooperation to improve global health
EMA experts meet with African regulators to discuss opportunities for collaboration. How to improve the availability of high quality, safe and effective medicines to patients in countries beyond Europe and how to make better use of existing tools? These were two of the questions discussed at a workshop jointly organised by the European Medicines Agency […]